Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Clomiphene (Clomid) | Testosterone Propionate | |
|---|---|---|
| Category | Hormones | Hormones |
| Standard Dose | Research indicates 25-50 mg daily or every other day for PCT/HPTA restart protocols. Clinical hypogonadism treatment: 25-50 mg daily. | Research indicates 25-50 mg administered every other day or 50-100 mg every 2-3 days via intramuscular or subcutaneous injection. |
| Timing | Take at the same time daily. Evening dosing may reduce perception of visual side effects. No food timing requirements. | Every-other-day or daily injection required due to short half-life. Rotate injection sites to minimize tissue irritation. |
| Cycle Duration | PCT protocols: 4-8 weeks. Long-term SERM monotherapy: 3-12 months with periodic reassessment. Zuclomiphene accumulation is a concern beyond 6 months. | Short cycles (4-8 weeks) or as bridge therapy. Not typically used for long-term TRT due to injection frequency burden. |
| Evidence Level | moderate_human | strong_human |
Clomiphene citrate is a racemic mixture of enclomiphene (trans-isomer, estrogen antagonist) and zuclomiphene (cis-isomer, weak estrogen agonist) that acts as a selective estrogen receptor modulator (SERM). It competitively occupies hypothalamic estrogen receptors, blocking the negative feedback of estradiol on GnRH pulse frequency. This disinhibition increases pulsatile GnRH release, stimulating anterior pituitary gonadotrope secretion of both LH and FSH, which in turn drives testicular testosterone synthesis and spermatogenesis. The zuclomiphene isomer has a much longer half-life (~30 days vs. ~10 days for enclomiphene), leading to tissue accumulation with chronic use.
Research indicates 25-50 mg daily or every other day for PCT/HPTA restart protocols. Clinical hypogonadism treatment: 25-50 mg daily.
Take at the same time daily. Evening dosing may reduce perception of visual side effects. No food timing requirements.
PCT protocols: 4-8 weeks. Long-term SERM monotherapy: 3-12 months with periodic reassessment. Zuclomiphene accumulation is a concern beyond 6 months.
Testosterone propionate is a short-acting esterified testosterone with a propionic acid ester, resulting in a half-life of approximately 0.8-1.5 days. Rapid hydrolysis by serum esterases produces a sharp testosterone spike followed by quick clearance. It activates the same androgen receptor-mediated genomic and non-genomic pathways as longer esters, but the pharmacokinetic profile demands frequent dosing. The short duration makes it useful for rapid onset situations and fine-tuned dose titration.
Research indicates 25-50 mg administered every other day or 50-100 mg every 2-3 days via intramuscular or subcutaneous injection.
Every-other-day or daily injection required due to short half-life. Rotate injection sites to minimize tissue irritation.
Short cycles (4-8 weeks) or as bridge therapy. Not typically used for long-term TRT due to injection frequency burden.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →